Literature DB >> 10725306

In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions.

J S Warrington1, R I Shader, L L von Moltke, D J Greenblatt.   

Abstract

The in vitro biotransformation of sildenafil to its major circulating metabolite, UK-103,320, was studied in human liver microsomes and in microsomes containing heterologously expressed human cytochromes. In human liver microsomes, the mean K(m) (+/-S.E. ) was 14.4 +/- 2.0 microM. A screen of the chemical inhibitors omeprazole (10 microM), quinidine (10 microM), sulfaphenazole (10 microM), and ketoconazole (2.5 microM) only revealed detectable inhibition with ketoconazole. Sildenafil biotransformation (36 microM) was inhibited by increasing concentrations of ketoconazole and ritonavir (IC(50) values less than 0.02 microM), which are established cytochrome P450 (CYP) 3A4 inhibitors. Using microsomes containing cDNA-expressed cytochromes, UK-103,320 formation was found to be mediated by four cytochromes: CYP3A4, -2C9, -2C19, and -2D6. Estimated relative contributions to net intrinsic clearance were 79% for CYP3A4 and 20% for CYP2C9; for CYP2C19 and -2D6, estimated contributions were less than 2%. These results demonstrate that CYP3A4 is the primary cytochrome mediating UK-103,320 formation and that drugs that inhibit CYP3A4 are likely to impair sildenafil biotransformation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725306

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  23 in total

1.  Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality. An intervention study on pages about sildenafil.

Authors:  Meret Martin-Facklam; Michael Kostrzewa; Peter Martin; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

2.  Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.

Authors:  Gideon A Paul; J Simon R Gibbs; Alan R Boobis; Allifia Abbas; Martin R Wilkins
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

3.  Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues.

Authors:  Nuggehally R Srinivas
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

4.  Pharmacokinetic interaction between Kaempferia parviflora extract and sildenafil in rats.

Authors:  Catheleeya Mekjaruskul; Bungorn Sripanidkulchai
Journal:  J Nat Med       Date:  2015-01-08       Impact factor: 2.343

Review 5.  Roles of sildenafil in enhancing drug sensitivity in cancer.

Authors:  Zhi Shi; Amit K Tiwari; Atish S Patel; Li-Wu Fu; Zhe-Sheng Chen
Journal:  Cancer Res       Date:  2011-05-24       Impact factor: 12.701

Review 6.  Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.

Authors:  Alberto Briganti; Andrea Salonia; Federico Deho'; Giuseppe Zanni; Luigi Barbieri; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2005-11-05       Impact factor: 4.226

7.  Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.

Authors:  R Hyland; E G Roe; B C Jones; D A Smith
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

8.  The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.

Authors:  Gary J Muirhead; Stephen Faulkner; Jane A Harness; Jörg Taubel
Journal:  Br J Clin Pharmacol       Date:  2002       Impact factor: 4.335

Review 9.  Safety of sildenafil in infants*.

Authors:  Samira Samiee-Zafarghandy; P Brian Smith; Johannes N van den Anker
Journal:  Pediatr Crit Care Med       Date:  2014-05       Impact factor: 3.624

10.  Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.

Authors:  V Sekar; E Lefebvre; T De Marez; M De Pauw; E De Paepe; T Vangeneugden; R M W Hoetelmans
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.